Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CNT005
MIFTS: 52

Central Nervous System Lymphoma

Categories: Blood diseases, Cancer diseases, Eye diseases, Immune diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Central Nervous System Lymphoma

About this section

MalaCards integrated aliases for Central Nervous System Lymphoma:

Name: Central Nervous System Lymphoma 12 15 17
Primary Central Nervous System Lymphoma 71
Primary Cns Lymphoma 12
Cns Lymphoma 71
Microglioma 12

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Immune diseases Blood diseases Neuronal diseases Eye diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3234
ICD9CM 34 200.5
NCIt 50 C9301
SNOMED-CT 67 307649006
UMLS 71 C0280803 C0742472
Sources

Summaries for Central Nervous System Lymphoma

About this section
Disease Ontology : 12 A hematologic cancer that has material basis in lymphoma located in central nervous system.

MalaCards based summary : Central Nervous System Lymphoma, also known as primary central nervous system lymphoma, is related to primary central nervous system lymphoma and intraocular lymphoma. An important gene associated with Central Nervous System Lymphoma is MYD88 (MYD88 Innate Immune Signal Transduction Adaptor), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Teniposide and Pemetrexed have been mentioned in the context of this disorder. Affiliated tissues include central nervous system, brain and liver, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Sources

Related Diseases for Central Nervous System Lymphoma

About this section

Diseases in the Central Nervous System Lymphoma family:

Primary Central Nervous System Lymphoma

Diseases related to Central Nervous System Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 631)
# Related Disease Score Top Affiliating Genes
1 primary central nervous system lymphoma 33.1 PAX5 MYD88 MGMT CXCR5 CXCL13 BCL6
2 intraocular lymphoma 32.2 PAX5 IL10 CXCR5 CXCL12 BCL6
3 lymphoproliferative syndrome 31.1 IL2 IL10 CCR6 BCL6
4 uveitis 31.0 IL6 IL2 IL10 CXCR5
5 toxoplasmosis 31.0 MYD88 IL6 IL10
6 intravascular large b-cell lymphoma 30.9 MYD88 BCL6
7 acquired immunodeficiency syndrome 30.8 TP53 MYC IL6 IL2 IL10 CXCR5
8 spinal cord lymphoma 30.7 CCR6 BCL6
9 testicular lymphoma 30.6 PDCD1LG2 MYD88 CD274 BCL6
10 graft-versus-host disease 30.6 IL6 IL2 IL10
11 retina lymphoma 30.6 IL10 CXCR5 CXCL13
12 neurosyphilis 30.6 IL10 CXCR5 CXCL13
13 plasmablastic lymphoma 30.6 PRDM1 MYC BCL6
14 b-cell non-hodgkin lymphoma 30.5 TNFSF13B IL10 BCL6
15 chorioretinitis 30.5 IL6 IL2 IL10
16 b-cell lymphoma 30.5 TP53 TNFSF13B PRDM1 PAX5 MYD88 MYC
17 lymphoblastic lymphoma 30.5 TP53 MYC BCL6
18 demyelinating disease 30.5 IL6 IL2 IL10 CCR6
19 monoclonal paraproteinemia 30.5 PRDM1 PAX5
20 peripheral t-cell lymphoma 30.5 TP53 IL2 CXCL13 CD274 BCL6
21 diffuse large b-cell lymphoma 30.5 TP53 TNFSF13B PRDM1 PAX5 MYD88 MYC
22 chickenpox 30.5 IL6 IL2 IL10 CCR6
23 reticulosarcoma 30.5 PAX5 MYC BCL6
24 posterior uveitis 30.4 IL6 IL2 CCR6
25 immune deficiency disease 30.4 TNFSF13B IL6 IL2 IL10 CXCR5 CXCL12
26 lymphoplasmacytic lymphoma 30.4 PAX5 MYD88 CXCL12 BCL6
27 viral encephalitis 30.3 TNFSF13B IL6 IL10 CCR6
28 t-cell adult acute lymphocytic leukemia 30.3 TP53 IL2 CCR6
29 thyroiditis 30.3 IL6 IL2 IL10
30 neuromyelitis optica 30.3 TNFSF13B IL6 CXCL13
31 marginal zone b-cell lymphoma 30.3 PAX5 MYD88 MALT1 CCR6 BCL6
32 panuveitis 30.3 IL6 IL10 CCR6
33 aphthous stomatitis 30.2 IL6 IL2 IL10
34 coronavirus infectious disease 30.2 IL6 IL10 CCR6
35 disease by infectious agent 30.2 IL6 IL2 IL10 CCR6
36 hepatitis b 30.2 TP53 MYD88 MYC IL6
37 meningoencephalitis 30.2 IL6 IL10 CCR6
38 exanthem 30.2 IL6 IL2 IL10 CD274 CCR6
39 bacterial infectious disease 30.2 MYD88 IL6 IL10 CCR6
40 klebsiella pneumonia 30.2 MYD88 IL6 IL10 CCR6
41 spinal cord disease 30.2 TNFSF13B IL6 IL2 IL10 CCR6
42 relapsing-remitting multiple sclerosis 30.2 TNFSF13B IL6 IL2 IL10 CCR6
43 b-lymphoblastic leukemia/lymphoma 30.2 PAX5 MYC CXCR5 CXCL13 CCR6
44 rubella 30.1 IL6 IL2 IL10
45 transverse myelitis 30.1 IL6 IL10 CCR6
46 myelitis 30.1 IL6 IL10 CCR6
47 hashimoto thyroiditis 30.1 PRDM1 IL6 IL10 CCR6
48 lymphoma, non-hodgkin, familial 30.1 TP53 TNFSF13B PAX5 MYD88 MYC MALT1
49 adult t-cell leukemia 30.0 TP53 MYC IL2 CD274 CCR6
50 lymphoma 30.0 TP53 PRDM1 PAX5 MYD88 MYC MGMT

Graphical network of the top 20 diseases related to Central Nervous System Lymphoma:



Diseases related to Central Nervous System Lymphoma
Sources

Symptoms & Phenotypes for Central Nervous System Lymphoma

About this section

GenomeRNAi Phenotypes related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

26 (show all 18)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-111 9.6 MGMT
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-12 9.6 CD274
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-120 9.6 CD274 PRDM1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-149 9.6 PRDM1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-152 9.6 PRDM1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-160 9.6 CD274
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-171 9.6 PRDM1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.6 PRDM1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 9.6 CD274
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-212 9.6 CD274
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.6 CD274
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-30 9.6 PRDM1
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-32 9.6 CD274
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-37 9.6 MGMT
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-59 9.6 MGMT
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.6 PRDM1
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 9.6 MGMT
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-99 9.6 PRDM1

MGI Mouse Phenotypes related to Central Nervous System Lymphoma:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.41 BCL6 CCR6 CD274 CXCL12 CXCL13 CXCR5
2 immune system MP:0005387 10.33 BCL6 CCR6 CD274 CXCL12 CXCL13 CXCR5
3 cellular MP:0005384 10.31 BCL6 CD274 CXCL12 CXCL13 CXCR5 IL10
4 homeostasis/metabolism MP:0005376 10.31 BCL6 CCR6 CD274 IL10 IL2 IL6
5 mortality/aging MP:0010768 10.22 BCL6 CD274 CXCL12 IL10 IL2 IL6
6 endocrine/exocrine gland MP:0005379 10.18 BCL6 IL10 IL2 IL6 MGMT MYC
7 liver/biliary system MP:0005370 10.07 BCL6 CXCL12 IL10 IL2 IL6 MYC
8 muscle MP:0005369 9.86 BCL6 CXCL12 IL10 IL6 MYC PAX5
9 neoplasm MP:0002006 9.85 IL10 IL2 IL6 MGMT MYC MYD88
10 no phenotypic analysis MP:0003012 9.7 BCL6 CD274 CXCL12 IL10 IL2 MGMT
11 normal MP:0002873 9.28 BCL6 CCR6 CXCL12 CXCR5 IL10 MYC
Sources

Drugs & Therapeutics for Central Nervous System Lymphoma

About this section

Drugs for Central Nervous System Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 124)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Teniposide Approved Phase 4 29767-20-2 34698
2
Pemetrexed Approved, Investigational Phase 4 150399-23-8, 137281-23-3 446556 60843
3
Fotemustine Investigational Phase 4 92118-27-9
4 Formoterol Fumarate Phase 4
5
Busulfan Approved, Investigational Phase 3 55-98-1 2478
6
Ifosfamide Approved Phase 3 3778-73-2 3690
7
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
8
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
9
Dalteparin Approved Phase 3 9005-49-6
10
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
11
Isophosphamide mustard Phase 3 100427
12 Heparin, Low-Molecular-Weight Phase 3
13 Fibrinolytic Agents Phase 3
14 Anticoagulants Phase 3
15
Benzocaine Approved, Investigational Phase 1, Phase 2 1994-09-7, 94-09-7 2337
16
tannic acid Approved Phase 1, Phase 2 1401-55-4
17
Vindesine Approved, Investigational Phase 2 53643-48-4, 59917-39-4 40839
18
Nedaplatin Approved, Investigational Phase 2 95734-82-0
19
Bortezomib Approved, Investigational Phase 1, Phase 2 179324-69-7 387447 93860
20
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
21
Ganciclovir Approved, Investigational Phase 2 82410-32-0 3454
22
Melphalan Approved Phase 2 148-82-3 4053 460612
23
Mesna Approved, Investigational Phase 2 3375-50-6 598
24
Mannitol Approved, Investigational Phase 1, Phase 2 69-65-8 453 6251
25
Obinutuzumab Approved, Investigational Phase 2 949142-50-1
26
Pembrolizumab Approved Phase 2 1374853-91-4
27
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
28
nivolumab Approved Phase 2 946414-94-4
29
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
30
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
31
Isavuconazole Approved, Investigational Phase 2 241479-67-4
32
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
33
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
34
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
35
Etoposide Approved Phase 2 33419-42-0 36462
36
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
37
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
38
leucovorin Approved Phase 2 58-05-9 6006
39
rituximab Approved Phase 2 174722-31-7 10201696
40
Idarubicin Approved Phase 2 58957-92-9 42890
41
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
42
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
43
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
44 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
45
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
46
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
47
Carmustine Approved, Investigational Phase 2 154-93-8 2578
48
Zidovudine Approved Phase 2 30516-87-1 35370
49
Hydroxyurea Approved Phase 2 127-07-1 3657
50
Tyrosine Approved, Investigational, Nutraceutical Phase 1, Phase 2 60-18-4 6057

Interventional clinical trials:

(show top 50) (show all 138)
# Name Status NCT ID Phase Drugs
1 The Prospective Study of FVD Program and HD-MTX-Ara-C Program Contrast in the Treatment of PCNSL Lymphoma. Unknown status NCT01960192 Phase 4 HD-MTX-Ara-C regimen;FVD regimen
2 Phase IV Study on the Role of Whole Brain Irradiation in Primary CNS Lymphoma (PCNSL) After High-dose Methotrexate Completed NCT00153530 Phase 4 methotrexate
3 Open Randomized Prospective Clinical Study of Rituximab Combined With Fotemustine, Pemetrexed, Dexamethasone Versus Rituximab Plus Methotrexate, Cytarabine, and Dexamethasone in the Treatment of Primary Central Nervous System Lymphoma Recruiting NCT04083066 Phase 4 rituximab in combination with methotrexate, cytarabine and dexamethasone
4 High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial Unknown status NCT02531841 Phase 3 Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®);Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
5 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
6 Treatment of Primary CNS Lymphoma With Systemic R-IDARAM Chemotherapy and Intrathecal Immunochemotherapy Recruiting NCT02657785 Phase 2, Phase 3 R-IDARAM plus intrathecal chemotherapy
7 Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With Primary CNS Lymphoma Recruiting NCT02836158 Phase 2, Phase 3 R-IDARAM plus intrathecal chemotherapy
8 Phase III Trial Evaluating Maintenance Treatment Versus Observation in Elderly Patients Suffering From Primary Central Nervous System Lymphoma in Complete Remission After High Dose Methotrexate Based Chemotherapy in First Line Recruiting NCT02313389 Phase 3 Rituximab, Methotrexate, Temozolomide
9 Busulfan+ Cyclophosphamide+ Etoposide Conditioning Regimen for Primary Central Nervous System Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplantation Recruiting NCT03733327 Phase 2, Phase 3 Busulfan (BU);Cyclophosphamide (CY);Etoposide (VP-16)
10 Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma Unknown status NCT02934204 Phase 2 methotrexate;temozolomide
11 Open-label Single Arm Phase II Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL) Unknown status NCT02779101 Phase 2 pembrolizumab
12 High-Dose Methotrexate Plus Steroid Followed by Concurrent Whole Brain Chemoradiation With Temozolomide for Immunocompetent Patients With Primary Central Nervous System Lymphoma - a Phase II Study Unknown status NCT00455286 Phase 2 Methotrexate;Methylprednisolone;Temozolomide
13 MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma Unknown status NCT02399189 Phase 2 R-MT followed by auto-HSCT
14 Ketogenic Diet Adjunctive to High Dose Methotrexate Chemotherapy for Primary Central Nervous System Lymphoma Unknown status NCT02983942 Phase 1, Phase 2
15 Immunochemotherapy in Primary Central Nervous System Lymphoma With Rituximab, HD-MTX, HD-Ara C, Cyclophosphamide, Ifosfamide, Vincristine, Vindesine, Temozolomide and DepoCyte Induction Followed by Maintenance Treatment in Elderly Patients With Temozolomide. Unknown status NCT01458730 Phase 2 Immunochemotherapy
16 Monoinstitutional Phase II Trial Addressing Tolerability and Activity of RCHOP Chemoimmunotherapy Preceded by BBB Permeabilization by t-NGR Necrosis Factor in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma Unknown status NCT03536039 Phase 2 NGR-hTNF;Doxorubicin;Cyclophosphamide;Vincristine;Prednisone
17 Treatment of HIV-Related Primary Central Nervous System Lymphoma (HIV-PCNSL): A Phase II Trial With Neoadjuvant Chemotherapy (High-Dose Methotrexate (MTX) Plus High-Dose Zidovudine) and Radiotherapy Unknown status NCT00003261 Phase 2 methotrexate;zidovudine
18 Plasma and Cerebrospinal Fluid (CSF) Pharmacokinetics of Bendamustine as a Component of Salvage Therapy for Primary Central Nervous System Lymphoma (PCNSL) Unknown status NCT03392714 Phase 2 R-B(O)AD
19 Phase 2 Study of Temsirolimus in Refractory and Recurrent Primary CNS Lymphoma Unknown status NCT00942747 Phase 2 temsirolimus
20 Multicenter Randomized Phase II Study of Methotrexate (MTX) and Temozolomide Versus MTX, Procarbazine, Vincristine and Cytarabine for Primary CNS Lymphoma (PCNSL) in the Elderly Unknown status NCT00503594 Phase 2 Methotrexate and temozolomide;Methotrexate , procarbazine ,vincristine ,cytarabine
21 Treatment of Patients Over 65 Years With Primary CNS Lymphoma: High-dose Methotrexate Combined With Chemo-immunotherapy Followed by Maintenance Therapy Unknown status NCT00989352 Phase 2 Methotrexate;Lomustine;Procarbazine;Rituximab
22 Phase â…¡ Trial of Temozolomide Plus Concurrent Whole-Brain Radiation Followed by TNV Regimen as Adjuvant Therapy for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (PCNSL) Unknown status NCT01735747 Phase 2 nedaplatin;vincristine;Temozolomide
23 Combination Chemotherapy (Methotrexate, Procarbazine And CCNU), Intraventricular Cytarabine And Methotrexate, +/- Intra-Ocular Chemotherapy For Patients With Primary Central Nervous System Lymphoma Completed NCT00074191 Phase 2 cytarabine;dexamethasone;lomustine;methotrexate;procarbazine hydrochloride
24 Combination Chemotherapy (Methotrexate, Cyclophosphamide, And Etoposide Phosphate) Delivered In Conjunction With Osmotic Blood-Brain Barrier Disruption (BBBD), With Intraventricular Cytarabine +/- Intra-Ocular Chemotherapy, In Patients With Primary Central Nervous System Lymphoma Completed NCT00074178 Phase 2 cyclophosphamide;cytarabine;dexamethasone;etoposide phosphate;methotrexate
25 Ex Vivo Expanded Megakaryocytes for Supportive Care of Breast Cancer Patients: A Phase I/II Study Completed NCT00006225 Phase 1, Phase 2
26 A Phase I Evaluation of the Combination of Pegylated Liposomal Doxorubicin (Doxil®) With PS-341 in Patients With Refractory Hematologic and Solid Malignancies Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
27 A Phase II Trial Of Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) Completed NCT02301364 Phase 2 Buparlisib (BKM120)
28 Open-label, Non-randomized, Phase 2 Study Evaluating Efficacy and Safety of PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma Completed NCT02669511 Phase 2 PQR309
29 AIDS-Related Primary Central Nervous System Lymphoma: A Phase II Pilot Study of High-Dose Intravenous Methotrexate With Rituximab Leucovorin Rescue and Highly Active Antiretroviral Therapy Completed NCT00267865 Phase 2 Methotrexate;Rituximab;Leucovorin
30 A Phase 2 Study of Idarubicin Based Combined Modality Therapy in Primary Central Nervous System Lymphoma Completed NCT00193973 Phase 2 Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C
31 Randomized Phase II Trial On Primary Chemotherapy With High-Dose Methotrexate And High-Dose Cytarabine With Or Without Thiotepa, And With Or Without Rituximab, Followed By Brain Irradiation Vs. High-Dose Chemotherapy Supported By Autologous Stem Cells Transplantation For Immunocompetent Patients With Newly Diagnosed Primary CNS Lymphoma Completed NCT01011920 Phase 2 Methotrexate;Ara-C;Rituximab;Thiotepa;BCNU
32 Randomized Phase II Trial on Primary Chemotherapy With High-dose Methotrexate, Alone or Associated With High-dose Cytarabine, Followed by Response- and Age-tailored Radiotherapy for Immunocompetent Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Completed NCT00210314 Phase 2 high dose methotrexate;high dose cytarabine
33 A Phase II Trial Of Induction Therapy With Zidovudine, Interleukin-2, And Ganciclovir In The Treatment Of HIV Positive Primary Central Nervous System Lymphoma Completed NCT00006264 Phase 2 ganciclovir;zidovudine
34 A Phase II Study of Intensive Methotrexate and Cytarabine Followed by High Dose Beam Chemotherapy With Autologous Peripheral Blood Progenitor Cell Transplantation in Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Completed NCT00003632 Phase 2 carmustine;cytarabine;etoposide;melphalan;methotrexate
35 Phase II Study Evaluating the Efficacy of Lenalidomide in Association With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma (PCNSL) Completed NCT01956695 Phase 2 Lenalidomide;Rituximab
36 Phase I/II Study Of Pre-Irradiation Chemotherapy With Methotrexate, Rituximab, And Temozolomide And Post -Irradiation Temozolomide For Primary Central Nervous System Lymphoma Completed NCT00068250 Phase 1, Phase 2 rituximab;methotrexate;temozolomide 100 mg/m^2;temozolomide 150 mg/m^2;temozolomide 200 mg/m^2;post-radiation therapy temozolomide
37 Evaluating the MBVP Chemotherapy Schedule Followed by Consolidating Radiotherapy in Non-AIDS Related Primary Central Nervous System Lymphoma (NAPCL) Completed NCT00003061 Phase 2 cytarabine;methotrexate
38 Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma Completed NCT00000801 Phase 2 Filgrastim;Vincristine sulfate;Doxorubicin hydrochloride;Cyclophosphamide;Cytarabine;Dexamethasone
39 Open-labeled, Multicenter Phase II Study of High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study Completed NCT01083342 Phase 2 MTX, MVD, VIA
40 Phase II Trial of Hihg-Dose Thiotepa, Busulfan, Cyclophosphamide, and Rituximab With Autologous Stem Cell Transplantation for Patients With CNS Involvement by Non-Hodgkin's Lymphoma or Primary CNS Lymphoma Completed NCT01182415 Phase 2 High-dose chemotherapy
41 Intensive Chemotherapy And Immunotherapy In Patients With Newly Diagnosed Primary CNS Lymphoma Completed NCT00098774 Phase 2 cytarabine;etoposide;leucovorin calcium;methotrexate;temozolomide
42 Hydroxyurea Treatment of EBV-Associated Primary CNS Lymphoma in Children and Adults With AIDS Completed NCT00002940 Phase 2 hydroxyurea
43 A Phase II Study of Methotrexate and Thiotepa Chemotherapy for Patients With Newly Diagnosed Primary CNS Lymphoma Completed NCT00045539 Phase 2 leucovorin calcium;methotrexate;thiotepa
44 Phase IB/II Study Combining the PI3K Inhibitor Copanlisib With the BTK Inhibitor Ibrutinib in Patients With Recurrent/Refractory Primary CNS Lymphoma Recruiting NCT03581942 Phase 1, Phase 2 Ibrutinib;Copanlisib
45 Randomized Phase II Trial on Fitness- and Comorbidity- Tailored Treatment in Elderly Patients With Newly Diagnosed Primary CNS Lymphoma (FIORELLA Trial) Recruiting NCT03495960 Phase 2 Rituximab;Methotrexate;Procarbazine;Lenalidomide;Temozolomide
46 Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma Following First Line Chemotherapy Treatment Recruiting NCT02623010 Phase 2 Imbruvica
47 A Single Arm, Multi-center, Phase II Clinical Trial of Rituximab, Lenalidomide Combined With High-dose Methotrexate and Temozolomide (RL-MT) in the First-line Treatment for Patients With Primary Central Nervous System Lymphoma Recruiting NCT04737889 Phase 2 Rituximab;Lenalidomide;Methotrexate;Temozolomide
48 An Exploratory Study on Camrelizumab（SHR-1210）for Recurrent Primary Central Nervous System Lymphoma (PCNSL) Recruiting NCT04070040 Phase 2 Camrelizumab
49 R2-MTX Regimen Combined With Lenalidomide Maintenance as Frontline Therapy for Primary Central Nervous System Lymphoma: a Multicenter Prospective Single Arm Trial. Recruiting NCT04120350 Phase 1, Phase 2 Methotrexate;Rituximab;Lenalidomide
50 A Phase Ib/II Study of Pembrolizumab, Ibrutinib and Rituximab in Recurrent Primary Central Nervous System Lymphoma (PCNSL) Recruiting NCT04421560 Phase 1, Phase 2 Ibrutinib;Pembrolizumab;Rituximab

Search NIH Clinical Center for Central Nervous System Lymphoma

Sources

Genetic Tests for Central Nervous System Lymphoma

About this section
Sources

Anatomical Context for Central Nervous System Lymphoma

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Central Nervous System Lymphoma:

19
Central Nervous System

MalaCards organs/tissues related to Central Nervous System Lymphoma:

40
Brain, Liver, T Cells, Spinal Cord, Pituitary, Bone Marrow, B Cells
Sources

Publications for Central Nervous System Lymphoma

About this section

Articles related to Central Nervous System Lymphoma:

(show top 50) (show all 2774)
# Title Authors PMID Year
1
Movement disorders in primary central nervous system lymphoma: two unreported cases and a review of literature. 61
33443666 2021
2
Absence of meaningful neurocognitive recovery in comatose patients with primary central nervous system lymphoma despite an effective response to chemotherapy: Case reports. 61
33575028 2021
3
Validation of combined use of DWI and percentage signal recovery-optimized protocol of DSC-MRI in differentiation of high-grade glioma, metastasis, and lymphoma. 61
32821962 2021
4
Primary central nervous system lymphoma mimicking autoimmune encephalitis: the role of autoantibody testing. 61
32990859 2021
5
Seizures in steroid-responsive encephalopathy. 61
33219869 2021
6
Inflammatory Brain Lesions as Omen of Primary Central Nervous System Lymphoma: A Case Report and Literature Review. 61
33557224 2021
7
New genetic prognostic biomarkers in primary central nervous system lymphoma (PCNSL). 61
33591648 2021
8
Consensus Recommendations for MRI and PET Imaging of Primary Central Nervous System Lymphoma: Guideline Statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). 61
33560416 2021
9
Correction to: In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy. 61
33595726 2021
10
Primary Central Nervous System Lymphoma: Evolving Biologic Insights and Recent Therapeutic Advances. 61
33288483 2021
11
A comparative study of multimodal magnetic resonance in the differential diagnosis of acquired immune deficiency syndrome related primary central nervous system lymphoma and infection. 61
33568094 2021
12
Evaluation of the Temporal Muscle Thickness as an Independent Prognostic Biomarker in Patients with Primary Central Nervous System Lymphoma. 61
33540564 2021
13
CSF interleukin 6 is a useful marker to distinguish pseudotumoral CNS inflammatory diseases from primary CNS lymphoma. 61
33609156 2021
14
High-dose methotrexate monotherapy for newly diagnosed primary central nervous system lymphoma: 15-year multicenter experience. 61
32978898 2021
15
Primary therapy and survival in patients aged over 70-years-old with primary central nervous system lymphoma: a contemporary, nationwide, population-based study in the Netherlands. 61
32241841 2021
16
Differentiating Glioblastoma from Primary Central Nervous System Lymphoma: the Value of Shapping and Nonenhancing Peritumoral Hyperintense Gyral Lesion on FLAIR Imaging. 61
33548537 2021
17
Primary Central Nervous System Lymphoma (PCNSL) - A Rare and Unusual Presentation of Rapidly Progressive Major Cognitive Dysfunction. 61
33527818 2021
18
Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ ALLG NHL 24 randomised controlled trial. 61
33560442 2021
19
Gamma knife stereotactic radiosurgery as an effective tool in primary CNS lymphoma: Evaluation of stereotactic radiosurgery and methotrexate treatment in a prospective and observational clinical research study. 61
33418336 2021
20
Spontaneously changing MRI findings of primary central nervous system vasculitis: A case report. 61
33246904 2021
21
Clinicopathologic significance of MYD88 L265P mutation and expression of TLR4 and P-STAT3 in primary central nervous system diffuse large B-cell lymphomas. 61
33079297 2021
22
Changing Incidence and Survival of Primary Central Nervous System Lymphoma in Australia: A 33-Year National Population-Based Study. 61
33499081 2021
23
[Different treatment regimens for primary central nervous system lymphoma:based on SEER database]. 61
33412634 2021
24
Sialic acid-binding immunoglobulin-like lectin-15 expression on peritumoral macrophages is a favorable prognostic factor for primary central nervous system lymphoma patients. 61
33441719 2021
25
Clinical significance of interleukin-10 concentration in the cerebrospinal fluid of patients with primary central nervous system lymphoma. 61
33240408 2021
26
Primary Central Nervous System Lymphoma Revealed by 68Ga-FAPI and 18F-FDG PET/CT. 61
33512949 2021
27
Diagnosis and treatment of primary central nervous system lymphoma with the primary lesion in the hypothalamus: a case report. 61
33430828 2021
28
Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. 61
32583848 2021
29
Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence. 61
33399078 2021
30
Venous Thromboembolism Prophylaxis with Low-Molecular-Weight Heparin in Primary Central Nervous System Lymphoma. 61
33296909 2021
31
Diversity of genetic alterations of primary central nervous system lymphoma in Hispanic versus non-Hispanic patients. 61
33581493 2021
32
SARS-CoV-2 infection in patients with primary central nervous system lymphoma. 61
33387015 2021
33
Clinical features and outcome of patients with primary central nervous system lymphoma admitted to the intensive care unit: a French national expert center experience. 61
33452932 2021
34
Primary Central Nervous System Lymphoma: Clinical Evaluation of Automated Segmentation on Multiparametric MRI Using Deep Learning. 61
32662130 2021
35
Assessment of Central Nervous System Lymphoma Based on CXCR4 Expression In Vivo Using 68Ga-Pentixafor PET/MRI. 61
33208624 2021
36
Exome sequencing identifies SLIT2 variants in primary CNS lymphoma. 61
33481259 2021
37
High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials. 61
33483528 2021
38
High 18F-FDOPA PET Uptake in Primary Central Nervous System Lymphoma. 61
32956128 2021
39
Editorial for: "Primary Central Nervous System Lymphoma: Clinical Evaluation of Automated Segmentation on Multiparametric MRI Using Deep Learning". 61
32770563 2021
40
Multiparametric-MRI-Based Radiomics Model for Differentiating Primary Central Nervous System Lymphoma From Glioblastoma: Development and Cross-Vendor Validation. 61
32864825 2021
41
A single-center retrospective analysis of outcome measures and consolidation strategies for relapsed and refractory primary CNS lymphoma. 61
33398532 2021
42
Impact of contemporary regimens on the outcomes and toxicity of primary CNS lymphoma: a single-center retrospective analysis of 73 patients. 61
33099747 2021
43
Imaging in Differentiating Cerebral Toxoplasmosis and Primary CNS Lymphoma With Special Focus on FDG PET/CT. 61
33112669 2021
44
Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy. 61
32981406 2021
45
Inflammatory Demyelinating Lesions: True Sentinel Lesion or Immune-Mediated Response to Lymphoma? 61
32949800 2021
46
Hemorrhagic Attitude in Frameless and Frame-Based Stereotactic Biopsy for Deep-Seated Primary CNS Lymphomas in Immunocompetent Patients: A Multi-Centric Analysis of the Last Twenty Years. 61
33476784 2021
47
Determination of cerebrospinal fluid adenosine deaminase activity cut-off for the diagnosis of tuberculous meningitis in Hong Kong. 61
32423993 2020
48
Deep-learned time-signal intensity pattern analysis using an autoencoder captures magnetic resonance perfusion heterogeneity for brain tumor differentiation. 61
33293590 2020
49
Seasonal variation in the incidence of primary CNS lymphoma. 61
33312676 2020
50
Primary Central Nervous System Lymphoma Presenting as Multifocal Brain Abscesses. 61
33489486 2020
Sources

Variations for Central Nervous System Lymphoma

About this section

Copy number variations for Central Nervous System Lymphoma from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 250739 9 21967751 21994490 Methylation deletion CDKN2A CNS lymphoma
Sources

Expression for Central Nervous System Lymphoma

About this section
Search GEO for disease gene expression data for Central Nervous System Lymphoma.
Sources

Pathways for Central Nervous System Lymphoma

About this section

Pathways related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.99 TP53 TNFSF13B PDCD1LG2 MYD88 MYC MALT1
2
ERK Signaling 63
Show member pathways
 13.78 TP53 TNFSF13B MYC IL6 IL2 IL10
3
PEDF Induced Signaling 63
Show member pathways
 13.61 TP53 TNFSF13B MYC IL6 IL2 IL10
4
Cytokine Signaling in Immune system 65
Show member pathways
 13.3 TP53 TNFSF13B MYD88 MYC IL6 IL2
5
PAK Pathway 63
Show member pathways
 13.22 TNFSF13B IL6 IL2 IL10 CXCR5 CXCL13
6
Akt Signaling 63
Show member pathways
 13.1 TP53 TNFSF13B MYD88 IL6 IL2 IL10
7
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.02 TP53 MYD88 MYC IL6 IL2 IL10
8
Pathways in cancer 36
12.81 TP53 MYC IL6 IL2 CXCL12
9
Measles 36
Show member pathways
 12.78 TP53 MYD88 MYC IL6 IL2
10
Allograft rejection 36 1
Show member pathways
 12.69 TNFSF13B IL6 IL2 IL10 CXCR5 CXCL13
11
NF-KappaB Family Pathway 63
Show member pathways
 12.62 TNFSF13B MYD88 MALT1 IL6 IL2 CXCL12
12
Immune response IL-23 signaling pathway 23
Show member pathways
 12.56 TP53 MYC IL6 IL2 IL10
13
T cell receptor signaling pathway 36
Show member pathways
 12.48 MYD88 MALT1 IL6 IL2 IL10 CD274
14
JAK-STAT signaling pathway 36
Show member pathways
 12.33 MYC IL6 IL2 IL10 CXCL12
15
Human T-cell leukemia virus 1 infection 36
12.3 TP53 MYC IL6 IL2
16
Folate Metabolism 1
Show member pathways
 12.29 TP53 MTR IL6 IL2
17
Tuberculosis 36
12.2 MYD88 MALT1 IL6 IL10
18
Transcriptional misregulation in cancer 36
12.18 TP53 PAX5 MYC IL6 BCL6
19
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.12 TP53 MYC IL6 IL2 IL10 CXCL12
20
C-type lectin receptor signaling pathway 36
Show member pathways
 12.11 MYD88 MALT1 IL6 IL2 IL10
21
Yersinia infection 36
12.05 MYD88 IL6 IL2 IL10
22
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.03 IL6 IL2 IL10 CXCR5 CXCL13 CXCL12
23
NF-kappaB Signaling 4
11.92 TNFSF13B PRDM1 PDCD1LG2 PAX5 MYD88 MALT1
24
NF-kappa B signaling pathway 36
11.88 TNFSF13B MYD88 MALT1 CXCL12
25
Spinal Cord Injury 1
11.85 TP53 TNFSF13B MYC IL6 IL2
26
IL6-mediated signaling events 1
Show member pathways
 11.79 PRDM1 MYC IL6
27
Interleukin-4 and 13 signaling 65
11.78 TP53 MYC IL6 IL10 BCL6
28
LT-BetaR Pathway 63
Show member pathways
 11.77 IL2 CXCL13 CXCL12
29
Glucocorticoid receptor regulatory network 1
11.76 TP53 IL6 IL2
30
Th1 Differentiation Pathway 64
Show member pathways
 11.73 IL6 IL2 IL10
31
Pertussis 36
11.72 MYD88 IL6 IL10
32
Dendritic Cells Developmental Lineage Pathway 64
11.71 IL6 IL2 IL10
33
Innate Lymphoid Cell Differentiation Pathways 64
11.71 IL2 IL10 CXCR5 CCR6
34
Photodynamic therapy-induced AP-1 survival signaling. 1
11.53 TP53 IL6 IL2
35
Hepatitis C and Hepatocellular Carcinoma 1
11.52 TP53 MYC IL6
36
IgA-Producing B Cells in the Intestine 64
11.52 TNFSF13B PRDM1 PDCD1LG2 PAX5 IL6 IL10
37
Malaria 36
11.51 MYD88 IL6 IL10
38
African trypanosomiasis 36
11.36 MYD88 IL6 IL10
39
IL-10 Pathway 63
11.32 MYC IL6 IL10
40
Cytokines and Inflammatory Response 1
11.21 IL6 IL2 IL10
41
G-protein signaling_Rap2B regulation pathway 23
10.97 TNFSF13B IL6 IL2 IL10 CXCL13 CXCL12
Sources

GO Terms for Central Nervous System Lymphoma

About this section

Cellular components related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.02 PDCD1LG2 CXCR5 CXCL12 CD274 CCR6

Biological processes related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.24 TNFSF13B MYD88 IL6 IL10 CXCR5 CXCL13
2 positive regulation of gene expression GO:0010628 10.02 TP53 PRDM1 MYD88 MYC IL6
3 immune system process GO:0002376 10.02 TNFSF13B PRDM1 PDCD1LG2 MYD88 IL2 CD274
4 regulation of cell proliferation GO:0042127 9.91 TP53 PRDM1 MYD88 BCL6
5 cytokine-mediated signaling pathway GO:0019221 9.87 TP53 MYD88 MYC IL6 IL2 IL10
6 positive regulation of cytosolic calcium ion concentration GO:0007204 9.86 IL2 CXCR5 CXCL13 CCR6
7 chemotaxis GO:0006935 9.85 CXCR5 CXCL13 CXCL12 CCR6
8 negative regulation of apoptotic process GO:0043066 9.81 TP53 MYD88 MYC MGMT MALT1 IL6
9 calcium-mediated signaling GO:0019722 9.8 SAMD14 CXCR5 CCR6
10 humoral immune response GO:0006959 9.77 PAX5 IL6 CCR6
11 cell chemotaxis GO:0060326 9.76 CXCR5 CXCL13 CXCL12 CCR6
12 T cell costimulation GO:0031295 9.75 TNFSF13B PDCD1LG2 CD274
13 negative regulation of T cell proliferation GO:0042130 9.71 PDCD1LG2 IL10 CD274
14 negative regulation of interferon-gamma production GO:0032689 9.7 PDCD1LG2 IL10 CD274
15 positive regulation of B cell proliferation GO:0030890 9.69 TNFSF13B IL2 BCL6
16 chemokine-mediated signaling pathway GO:0070098 9.67 CXCR5 CXCL13 CXCL12 CCR6
17 positive regulation of T cell proliferation GO:0042102 9.65 TNFSF13B PDCD1LG2 IL6 IL2 CD274
18 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.63 TP53 IL6
19 negative regulation of B cell apoptotic process GO:0002903 9.62 IL2 BCL6
20 response to peptidoglycan GO:0032494 9.61 MYD88 IL6
21 positive regulation of immunoglobulin production GO:0002639 9.61 IL6 IL2 IL10
22 germinal center formation GO:0002467 9.6 CXCL13 BCL6
23 positive regulation of interleukin-17 production GO:0032740 9.58 MYD88 IL6 IL2
24 type 2 immune response GO:0042092 9.57 IL10 BCL6
25 cellular response to lipopolysaccharide GO:0071222 9.5 PDCD1LG2 MYD88 MALT1 IL6 IL10 CXCL13
26 positive regulation of plasma cell differentiation GO:1900100 9.49 IL2 IL10
27 immune response GO:0006955 9.32 TNFSF13B PDCD1LG2 IL6 IL2 IL10 CXCR5

Molecular functions related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein self-association GO:0043621 9.43 TP53 MYD88 MALT1
2 growth factor activity GO:0008083 9.26 IL6 IL2 IL10 CXCL12
3 kinase activator activity GO:0019209 9.16 MALT1 IL2
4 cytokine activity GO:0005125 9.1 TNFSF13B IL6 IL2 IL10 CXCL13 CXCL12
Sources

Sources for Central Nervous System Lymphoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....